Deal snapshot: AMGEN TO REACQUIRE PRODUCT RIGHTS THREE PRODUCTS FROM GSK.
US-based biotechnology company Amgen (NASDAQ: AMGN) has entered into a definitive agreement with UK-based drugmaker GSK to reacquire all of its remaining rights to Prolia (denosumab), Xgeva (denosumab) and Vectibix (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world, the company said.
The agreement involves key expansion markets for Amgen including Brazil, China, Colombia, Hong Kong, Israel, Singapore, South Korea, Taiwan and Thailand. GSK has held select regional rights to Prolia and Xgeva since 2009 and to Vectibix since 2010 under license from Amgen.
Target: rights to Prolia (denosumab), Xgeva (denosumab) and Vectibix (panitumumab) in 48 countries
Deal size in USD:
Type: Corporate Acquisition
Buyer advisor: , ,
Comment: Amgen buys back rights to three drugs/in 48 countries
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Dec 16, 2015|
|Previous Article:||Deal snapshot: ARBOR INVESTMENTS ACQUIRES DPI SPECIALTY FOODS.|
|Next Article:||Deal snapshot: VISTRA GROUP BUYS MALTA YACHT SERVICE PROVIDER.|